Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Avitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hangzhou ACEA Pharmaceutical Research
  • Most Recent Events

    • 26 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.
    • 06 Jun 2017 Results (n=16) assessing safety, the intracranial/extracranial efficacy, and the blood brain barrier (BBB) penetration rate of Avitinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top